Evidence map›Paper›PMID 33378390›Full record

ArticlePloS one2020

Triphenylphosphonium derivatives disrupt metabolism and inhibit melanoma growth in vivo when delivered via a thermosensitive hydrogel.

Kyle C Kloepping, Alora S Kraus, Devin K Hedlund, Colette M Gnade, Brett A Wagner, Michael L McCormick, Melissa A Fath, Dongrim Seol, Tae-Hong Lim, Garry R Buettner and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Mitoquinone mesylate attenuates pathological features of lean and obese allergic asthma in mice.American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Kyle C KloeppingDepartment of Radiology, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Alora S KrausDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Devin K HedlundDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Colette M GnadeDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Brett A WagnerDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Michael L McCormickDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Melissa A FathDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Dongrim SeolDepartment of Orthopedic Surgery, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Tae-Hong LimDepartment of Biomedical Engineering, College of Engineering, The University of Iowa, Iowa City, IA, United States of America.
Garry R BuettnerDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Prabhat C GoswamiDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
F Christopher PiggeDepartment of Chemistry, The University of Iowa, Iowa City, IA, United States of America.
Douglas R SpitzDepartment of Radiation Oncology, Free Radical Radiation Biology Program, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
Michael K SchultzDepartment of Radiology, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States of America.
University of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Project 3: MRI Imaging of Redox Active Fe Predicts GBM Responses to Pharmacological AscorbateP01CA217797 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 2018 to 2022
$9.6M
TRAINING PROGRAM IN FREE RADICAL AND RADIATION BIOLOGYT32CA078586 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 1999 to 2024
$5.7M
PREDOCTORAL TRAINING PROGRAM IN BIOTECHNOLOGYT32GM008365 · NIGMS · UNIVERSITY OF IOWA · PI KERNS, ROBERT JOHN · 1990 to 2021
$3.8M
Enhancing Metabolic Oxidative Stress and Therapy Responses in Cancer Stem CellsR01CA182804 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 2014 to 2018
$1.7M
Repurposing redox active agents for exploiting differences in cancer cell metabolism for improving cancer therapyR50CA243693 · NCI · UNIVERSITY OF IOWA · PI FATH, MELISSA ANN · 2019 to 2023
$776k
Mitochondrial Targeted Metastatic Melanoma TherapyK25CA172218 · NCI · UNIVERSITY OF IOWA · PI SCHULTZ, MICHAEL KING · 2013 to 2017
$753k
NCI NIH HHS K25 CA172218NCI NIH HHS P01 CA217797NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA182804NCI NIH HHS R50 CA243693NCI NIH HHS T32 CA078586NIGMS NIH HHS T32 GM008365
6 · The paper itself

Abstract

Despite dramatic improvements in outcomes arising from the introduction of targeted therapies and immunotherapies, metastatic melanoma is a highly resistant form of cancer with 5 year survival rates of <35%. Drug resistance is frequently reported to be associated with changes in oxidative metabolism that lead to malignancy that is non-responsive to current treatments. The current report demonstrates that triphenylphosphonium(TPP)-based lipophilic cations can be utilized to induce cytotoxicity in pre-clinical models of malignant melanoma by disrupting mitochondrial metabolism. In vitro experiments demonstrated that TPP-derivatives modified with aliphatic side chains accumulated in melanoma cell mitochondria; disrupted mitochondrial metabolism; led to increases in steady-state levels of reactive oxygen species; decreased total glutathione; increased the fraction of glutathione disulfide; and caused cell killing by a thiol-dependent process that could be rescued by N-acetylcysteine. Furthermore, TPP-derivative-induced melanoma toxicity was enhanced by glutathione depletion (using buthionine sulfoximine) as well as inhibition of thioredoxin reductase (using auranofin). In addition, there was a structure-activity relationship between the aliphatic side-chain length of TPP-derivatives (5-16 carbons), where longer carbon chains increased melanoma cell metabolic disruption and cell killing. In vivo bio-distribution experiments showed that intratumoral administration of a C14-TPP-derivative (12-carbon aliphatic chain), using a slow-release thermosensitive hydrogel as a delivery vehicle, localized the drug at the melanoma tumor site. There, it was observed to persist and decrease the growth rate of melanoma tumors. These results demonstrate that TPP-derivatives selectively induce thiol-dependent metabolic oxidative stress and cell killing in malignant melanoma and support the hypothesis that a hydrogel-based TPP-derivative delivery system could represent a therapeutic drug-delivery strategy for melanoma.

Indexed as

AnimalsAuranofinButhionine SulfoximineCell Line, TumorCell SurvivalDelayed-Action PreparationsDrug SynergismFemaleHumansHydrogelsMelanomaMiceMitochondriaOrganophosphorus CompoundsOxidative StressStructure-Activity RelationshipAuranofinButhionine SulfoximineDelayed-Action PreparationsHydrogelsOrganophosphorus Compounds

Identifiers

PMID33378390
PMCPMC7773266
OpenAlexW3114638377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.